학술논문
Cardiovascular outcomes of patients treated for non-Hodgkin lymphoma with first-line doxorubicin-based chemotherapy.
Document Type
Article
Author
Zduniak, Alexandra; Lévêque, Emilie; Perdrix, Anne; Etancelin, Pascaline; Ménard, Anne-Lise; Lenain, Pascal; Contentin, Nathalie; Pépin, Louis-Ferdinand; Leprêtre, Stéphane; Lemasle, Emilie; Lanic, Hélène; Stamatoullas-Bastard, Aspasia; Kammoun-Quique, Leila; Tilly, Hervé; Bauer, Fabrice; Jardin, Fabrice; Camus, Vincent
Source
Subject
*DIFFUSE large B-cell lymphomas
*NON-Hodgkin's lymphoma
*CARDIOTOXICITY
*HEART valve diseases
*CORONARY disease
*
*
*
*
Language
ISSN
1042-8194
Abstract
We conducted a single-center retrospective study to assess cardiovascular (CV) toxicity and treatment discontinuation for CV toxicity in diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) patients treated with immunochemotherapy (R-CHOP-like). Between 2006 and 2017, 433 patients were included (DLBCL: n = 345, FL: n = 88). The median age was 63 years (50–73). We defined three types of CV toxicity: early-onset cardiovascular toxicity (the event occurred within 6 months following treatment start); subacute toxicity (the event occurred between 6 months and 1 year after treatment start) and late toxicity (the event occurred 1 year or more after treatment start). Forty-eight (11.1%) patients experienced at least one anthracycline-related CV event. Seven patients experienced treatment discontinuation due to CV toxicity. Early-onset and subacute cardiac events were primarily acute heart failure (34.3%) and atrial fibrillation (28.6%). History of ischemic heart disease (p = 0.02) and valvular heart disease (p = 0.03) were associated with a higher risk of anthracycline-related CV event occurrence. [ABSTRACT FROM AUTHOR]